Find information on thousands of medical conditions and prescription drugs.

Argatroban

Argatroban is an anticoagulant that is a small molecule direct thrombin inhibitor. In 2000, argatroban was licensed by the FDA for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia. In 2002, it was approved for use during percutaneous coronary interventions in patients who have or at risk for developing HIT. more...

Home

Abelcet

Abilify

Abreva

Accure

Acetylcholine chloride

Acilac

Aciphex

Acitretin

Actifed

Actigall

Actiq

Actisite

Actonel

Actos

Acular

Adalat

Advicor

Advil

Aerobid

Aerolate

Afrinol

Aggrenox

Agomelatine

Agrylin

Airomir

Alanine

Alavert

Albendazole

Alcaine

Alclometasone

Aldomet

Aldosterone

Alesse

Aleve

Alfenta

Alfentanil

Alfuzosin

Alimta

Alkeran

Allegra

Alora

Alpidem

Altace

Amaryl

Ambien

Amicar

Amitraz

Amoxil

Anaprox

Ancef

Android

Anexsia

Apidra

Aranesp

Arava

Arestin

Aricept

Arixtra

Artane

Asacol

Asmalix

Aspirin

Atacand

Atarax

Ativan

Atridox

Avandia

Avapro

Avinza

Avizafone

Avobenzone

Avodart

Axid

Axotal

Argatroban is given intravenously. Argatroban is metabolized in the liver and has a half life of about 50 minutes. It is monitored by PTT. Because of its hepatic metabolism, it may be used in patients with renal dysfunction. (This is in contrast to lepirudin, a direct thrombin inhibitor that is primarily renally cleared).

It is manufactured by GlaxoSmithKline.

Reference

Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med 2005;353:1028-40. PMID 16148288.

Read more at Wikipedia.org

• [List your site here Free!]


	New & Approved.(Brief Article) : An article from: Family Practice News $5.95	Clinical Management of Thrombotic and Cardiovascular Disorders With Thrombin Inhibitors, the Role of Argatroban: The Role of Argatroban $25.25


Mitsubishi Pharma Launches Selective Antithrombin Agent Argatroban in Germany Tokyo, Japan, July 21, 2005 - (JCNN) - Mitsubishi Pharma (TSE: 4509) announced July 20 that its overseas subsidiary Mitsubishi Pharma Europe of London ... From JCNN News Summaries, 7/22/05

Argatroban a new treatment option for heparin-induced thrombocytopenia - Pharmacology Heparin is commonly used to prevent thrombosis in patients undergoing surgery and in nonambulatory patients in critical care units. Heparin-induced thrombocytopenia (HIT) is a rare and serious comp From Critical Care Nurse, 12/1/03 by Kevin W. Cleveland

Argatroban - New & Approved (Texas Biotechnology, GlaxoSmithKline) A synthetic direct thrombin inhibitor, approved for use as an anticoagulant for people who have or who are at risk of heparin-induced thrombocytopenia (HIT) From OB/GYN News, 5/15/02 by Elizabeth Mechcatie

FDA Approval of Argatroban The U.S. Food and Drug Administration (FDA) has approved the anticoagulant argatroban for the prevention and treatment of thrombosis associated with ... From American Family Physician, 1/1/01 by Monica Preboth

Argatroban Use In Patients With Heparin-Induced Thrombocytopenia During Percutaneous Coronary Intervention - Abstract Bruce E Lewis, MD(*); Marc Cohen, MD; Fred Leya, MD; William Matthai, Jr, MD and the ARG-216/310/311 Investigators, Cardiology, Loyola University Medical ... From CHEST, 10/1/00 by Bruce E Lewis

Finding haystacks full of needles: from opus to osler When we compose medical school curricula, we choose what to stress to our students based on how common or how instructive the disease is. What are the ... From CHEST, 5/1/05 by Robert L. Levine

The management of patients with heparin-induced thrombocytopenia who require anticoagulant therapy For patients with heparin-induced thrombocytopenia (HIT), reexposure to heparin is generally not recommended. However, these patients are likely to require anticoagulation therapy at some point in From CHEST, 2/1/05 by Kathryn Hassell

Cases of heparin-induced thrombocytopenia elucidate the syndrome Patients with heparin-induced thrombocytopenia (HIT) can have a dramatic presentation and often an unfortunate outcome. Each episode has the real potential ... From CHEST, 2/1/05 by Lawrence Rice

Home

Contact

Resources

Exchange Links

ebay